Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients-Reference-Cited by-同舟云学术

Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients

Published:2014-02 Issue:1 Volume:36 Page:71-79
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Elens Laure,Hesselink Dennis A.,Bouamar Rachida,Budde Klemens,de Fijter Johannes W.,De Meyer Martine,Mourad Michel,Kuypers Dirk R. J.,Haufroid Vincent,van Gelder Teun,van Schaik Ron H. N.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference36 articles.

1. . Clinical pharmacokinetics of tacrolimus.;Venkataramanan;Clin Pharmacokinet,1995

2. . Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.;Dai;Drug Metab Dispos,2006

3. . In vitro metabolism of cyclosporine A by human kidney CYP3A5.;Dai;Biochem Pharmacol,2004

4. . Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.;Kamdem;Clin Chem,2005

5. . Genetic contribution to variable human CYP3A-mediated metabolism.;Lamba;Adv Drug Deliv Rev,2002

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients;International Immunopharmacology;2024-08

2. Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review;Pharmacogenomics;2024-05-02

3. Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies;BMC Nephrology;2024-02-06

4. The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients;Clinical and Translational Science;2024-02

5. Effect of CYP3A4*22, CYP3A5*3 and POR*28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients;Pharmacogenetics and Genomics;2023-12-04